ZyVersa Therapeutics, Inc. (ZVSA)
| Market Cap | 803.12K -23.7% |
| Revenue (ttm) | n/a |
| Net Income | -24.49M |
| EPS | -3.40 |
| Shares Out | 8.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 960 |
| Open | 0.0990 |
| Previous Close | 0.1030 |
| Day's Range | 0.0990 - 0.0992 |
| 52-Week Range | 0.0774 - 0.3000 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical d... [Read more]
Financial Performance
Financial StatementsNews
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
LIGHTHOUSE POINT, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatmen...
ZyVersa Therapeutics Quarterly report: Q1 2026
ZyVersa Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
ZyVersa Therapeutics Earnings release: Q1 2026
ZyVersa Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation d...
ZyVersa Therapeutics Annual report: Q4 2025
ZyVersa Therapeutics has published its Q4 2025 annual report on March 31, 2026.
ZyVersa Therapeutics Earnings release: Q4 2025
ZyVersa Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatme...
ZyVersa Therapeutics Earnings release: Q3 2025
ZyVersa Therapeutics released its Q3 2025 earnings on November 19, 2025, summarizing the period's financial results.
ZyVersa Therapeutics Quarterly report: Q3 2025
ZyVersa Therapeutics has published its Q3 2025 quarterly earnings report on November 19, 2025.
ZyVersa Therapeutics highlights publication of data on inflammasome inhibitors
ZyVersa Therapeutics (ZVSA) highlights data from a peer-reviewed article, The Role of NLRP3 Inflammasome in Type 2 Diabetes Mellitus and Its Macrovascular Complications, recently published in the Jour...
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. ...
ZyVersa Therapeutics highlights lipidomic data in Alport Syndrome, DKD
ZyVersa Therapeutics (ZVSA) highlights key data from a recently published study, Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome, designed to elucidate how disrupted lipid metaboli...
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.
ZyVersa Therapeutics highlights data on role of lipotoxicity in DKD
ZyVersa Therapeutics (ZVSA) highlights key data on the role of lipotoxicity in the development and progression of DKD from a review article, Targeting lipid metabolic reprogramming to alleviate diabet...
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
Lipid accumulation in the kidneys' filtration system results in inflammation and fibrosis that cause progressive kidney damage and disease progression.
ZyVersa Therapeutics reports Q2 EPS (46c) vs. ($3.31) last year
“I am pleased to announce that we are well positioned to achieve our near-term development milestones,” said Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO, and President. “In June and July…
ZyVersa Therapeutics expects cash to fund requirements on month-to-month basis
The company said, “Based on our current operating plan, we expect our cash and cash equivalents will only be sufficient to fund operating expenses and capital expenditure requirements on a…
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is und...
ZyVersa Therapeutics Earnings release: Q2 2025
ZyVersa Therapeutics released its Q2 2025 earnings on August 13, 2025, summarizing the period's financial results.
ZyVersa Therapeutics Quarterly report: Q2 2025
ZyVersa Therapeutics has published its Q2 2025 quarterly earnings report on August 13, 2025.
ZyVersa Therapeutics Registration statement: Registration Filing
ZyVersa Therapeutics filed a registration statement on August 1, 2025, providing details about a securities offering with the SEC.
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...
ZyVersa Therapeutics Registration statement: Registration Filing
ZyVersa Therapeutics filed a registration statement on July 18, 2025, providing details about a securities offering with the SEC.
ZyVersa announces warrant inducement transaction for $2M in gross proceeds
ZyVersa Therapeutics (ZVSA) announced its entry into a warrant inducement agreement with a single institutional investor of the company. Terms of the warrant inducement agreement include the immediate...
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment...